| Literature DB >> 23393563 |
Cuiling Xu1, A Danielle Iuliano, Min Chen, Po-Yung Cheng, Tao Chen, Jinghong Shi, Jing Yang, Lijie Wang, Fan Yuan, Marc-Alain Widdowson, Yuelong Shu.
Abstract
BACKGROUND: Influenza A (H1N1)pdm09 (2009 H1N1) re-circulated as the predominant virus from January through February 2011 in China. National surveillance of 2009 H1N1 as a notifiable disease was maintained to monitor potential changes in disease severity from the previous season. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2013 PMID: 23393563 PMCID: PMC3564919 DOI: 10.1371/journal.pone.0055016
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of enrollment of hospitalized cases with confirmed Influenza A(H1N1)pdm09 infection from November 2010 to May 2011.
Figure 2Hospitalized patients with influenza A (H1N1)pdm09 infection by date of symptom onset, China, from September 2009 to May 2011.
Figure 3Risk ratio and percentage of hospitalizations and death by age group, China, during the winter season of 2010–2011 and during the 2009 pandemic period.
Demographic characteristics, chronic medical condition and treatment of hospitalized cases with influenza A (H1N1)pdm09 infection (N = 701).
| Characteristics | Hospitalized Patients with chart review n = 701 | Moderately ill Patients n = 475 | Severe Patients | ||
| Subtotal n = 226 | Admitted to ICU n = 149 | Death n = 77 | |||
| Age, median (IQR), years | 22 (3–46) | 14 (2–41) | 30 (6–55) | 27 (4–55) | 39 (25–53) |
| Male sex | 411 (58.6) | 271 (57.1) | 140 (62.0) | 99 (66.4) | 41 (53.3) |
| At least 1 underlying medical condition | 228 (32.5) | 121 (25.5) | 107 (47.4) | 66 (44.3) | 41 (53.3) |
| Cardiovascular disease | 79 (11.3) | 43 (9.1) | 36 (15.9) | 23 (15.4) | 13 (16.9) |
| Chronic lung disease | 78 (11.1) | 50 (10.5) | 28 (12.4) | 24 (14.8) | 6 (7.8) |
| Metabolic disease | 51 (7.3) | 24 (5.1) | 27 (12.0) | 18 (12.1) | 9 (11.7) |
| Chronic hepatic disease | 39 (5.6) | 25 (5.3) | 14 (6.2) | 8 (5.4) | 6 (7.8) |
| Immunosupression | 36 (5.1) | 15 (3.2) | 21 (9.3) | 8 (5.4) | 13 (16.9) |
| Chronic renal disease | 28 (4.0) | 13 (2.7) | 15 (6.6) | 10 (6.7) | 5 (6.5) |
| Neurological disease | 14 (2.0) | 7 (1.5) | 7 (3.1) | 6 (4.0) | 1 (1.3) |
| Guillainbarre syndrome | 2 (0.3) | 1 (0.2) | 1 (0.4) | 1 (0.7) | 0 (0) |
| Vaccination | |||||
| Seasonal flu vaccination during 2009–2010 | 9 (5.6) | 7 (9.2) | 2 (2.3) | 1 (2.2) | 1 (2.4) |
| Pandemic H1N1 vaccination | 2 (1.2) | 0 (0) | 2 (2.2) | 1 (2.0) | 1 (2.3) |
| Obesity among non-pregnant patients≥2 yrs of age with known information | 71 (17.3) | 41 (16.9) | 30 (17.9) | 21 (19.4) | 9 (15.0) |
| Pregnancy among female patients ofreproductive age (15–49 year-old) | 56 (48.7) | 30 (45.5) | 26 (53.1) | 15 (55.6) | 11 (50.0) |
| Days from symptom onset to hospitaladmission, Median(IQR) | 3 (1–5) | 2 (1–5) | 4 (2–7) | 3 (1–6) | 4 (2–7) |
| Antiviral treatment | 359 (55.9) | 191 (43.6) | 168 (82.4) | 115 (85.8) | 53 (75.7) |
| Antiviral treatment initiated beforehospital admission | 8 (2.3) | 5 (2.8) | 3 (1.7) | 3 (2.5) | 0 (0) |
| Antiviral treatment initiation time,median days (IQR) | 5 (2–7) | 4 (2–7) | 5 (3–8) | 5.0 (3–7) | 7 (4–9) |
NOTE. Data are no. (%) of patients, unless otherwise indicated. All patients who died had been admitted to an ICU.
Figure 4Days from symptom onset to antiviral treatment initiation among Hospitalized cases with influenza A (H1N1)pdm09 infection, China, during the winter season of 2010–2011 (n = 342).
Bar labels in the left side of each bar denote percent of hospitalized cases within 2 Days from symptom onset to Antiviral treatment initiation. Bar labels in the right side of each bar denote percent of hospitalized cases within 4 Days from symptom onset to Antiviral treatment initiation.
Factors associated with severe illness due to influenza A (H1N1)pdm09 among non-pregnant cases aged ≥2 years.
| Characteristics | No. of moderately ill patients (%) n = 342 | No. of severe patients (%) n = 188 |
|
| ||
|
|
|
|
| |||
| Male, sex | 213 (62.3) | 132 (70.2) | 1.43 (0.98–2.09) | 0.07 | 1.69 (1.09–2.63) | <0.05 |
| Age, years | ||||||
| 2–17 | 146 (42.7) | 55 (29.3) | Ref | Ref | ||
| 18–49 | 110 (32.2) | 65 (34.6) | 1.57 (1.01–2.43) | 0.68 | 1.06 (0.63–1.80) | 0.80 |
| ≥50 | 86 (25.2) | 68 (36.2) | 2.10 (1.35–3.27) | <0.01 | 1.01 (0.56–1.83) | 0.93 |
| At least 1 underlying medical condition | 106 (31.0) | 100 (53.2) | 2.53 (1.75–3.65) | <0.0001 | 2.50 (1.54–4.06) | <0.01 |
| Days from symptom onset to hospital admission | ||||||
| On symptom day 0–2 | 189 (55.4) | 71 (38.4) | Ref | Ref | ||
| On symptom day ≥3 | 152 (44.6) | 114 (61.6) | 2.00 (1.39–2.88) | <0.001 | 2.00 (1.30–3.04) | <0.01 |
| Days from symptom onset to antiviral treatment initiation | ||||||
| On symptom day 0–2 | 51 (34.9) | 23 (17.4) | ||||
| On symptom day 3–4 | 35 (24.0) | 34 (25.8) | 2.15 (1.09–4.23) | 0.37 | 1.64 (0.77–3.49) | 0.81 |
| On symptom day >5 | 60 (41.1) | 75 (56.8) | 2.77 (1.52–5.04) | <0.01 | 3.12 (1.54–6.35) | <0.01 |
The Chi-square test was performed unless otherwise indicated.
In the multivariate analysis, none of the two-way interaction terms was significant.
Only patients who received antivirus treatment were included in the analysis.